They used the CRMP2 phosphorylation inhibitor (S)-lacosamide to scrutinize the impact of CRMP2 phosphorylation at S522 on tumor growth and discovered that inhibiting CRMP2 phosphorylation with (S)-lacosamide reduced glioblastoma cell growth in all glioblastoma cell lines and also used showed that (S)-lacosamide inhibits glioblastoma growth in vivo models [96]. The gene discussed is DPYSL2; the disease is glioblastoma.